The early pathogenesis of preeclampsia (PE) involves a systemic inflammatory immune response. Recent data demonstrate that increased circulating arginine vasopressin (AVP) in humans is predictive of PE and that infusion of AVP in mouse dams phenocopies the pregnancy-specific cardiovascular and immune alterations observed in human PE. Specifically, AVP suppresses anti-inflammatory cytokines and cells. Betamethasone (BMTZ), commonly given to women at risk for preterm birth, is both an AVP and immune response modulator. We hypothesize that early treatment with BMTZ will prevent the development of AVP-induced PE.
The authors report no conflict of interest.
Copyright © The authors, 2018.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Scroggins SM, Santillan DA, Sandgren JA, Pierce GL, Sigmund CD, Grobe JL, Santillan MK. Betamethasone: a novel therapeutic intervention for preeclampsia. Proc Obstet Gynecol. 2018 Oct 29;8(3):Article 19 [2 p.]. https://doi.org/10.17077/2154-4751.1432. Free full text article.